CNBC
03 Feb 2026, 17:06 UTC · 38w ago
Impact · against what's priced in
Novo Nordisk faces a severe valuation reset as forecasted sales and profit declines of 5-13% for 2026 significantly exceed market expectations. Eli Lilly benefits as the primary competitor capturing U.S. market share and preparing a rival oral GLP-1 treatment.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
Novo Nordisk forecasts a 5% to 13% decline in both sales and operating profit for 2026, significantly missing analyst expectations.
So whatA projection of shrinking revenue and profit for a growth-stock pharmaceutical giant is a major negative catalyst for valuation.
More negative than 99% of claims this week
Novo Nordisk will lose exclusivity for Wegovy and Ozempic in China, Brazil, and Canada in 2026.
So whatLoss of exclusivity allows generic competition, permanently eroding margins and market share in these key regions.
Continue reading
5 related stories
The company's forecast of a 5% to 13% decline in sales and operating profit for 2026, combined with loss of exclusivity in China, Brazil, and Canada, represents a significant downward shift in growth expectations.
Read from the article alone
No priced-in read yet
Eli Lilly has already surpassed Novo Nordisk in U.S. market share with more effective drugs and is expected to launch its own weight loss pill in the first half of 2026.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 95% of claims this week
The company expects sales declines in the U.S. due to pricing headwinds and increased competition from Eli Lilly.
So whatThe U.S. is Novo's largest market; negative growth here suggests a loss of competitive advantage in the GLP-1 space.
More negative than 91% of claims this week
Novo Nordisk has launched the oral version of Wegovy in the U.S. and is developing the CagriSema injectable to regain market share.
So whatNew product forms and next-gen drugs provide the only viable path to reversing the projected 2026 decline.
More positive than 76% of claims this week
Novo and Eli Lilly reached an agreement with the U.S. administration to cut prices for Medicare, Medicaid, and direct-to-consumer sales via TrumpRx.gov in 2026.
So whatWhile intended to increase volume, explicit price cuts typically compress top-line revenue and margins.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 92% of ticker scores this week
Shares plummeted after the company forecasted declining sales and profit growth due to pricing headwinds and loss of exclusivity.
More positive than 64% of ticker scores this week
Mentioned as a strong competitor that has surpassed Novo Nordisk in U.S. market share with more effective drugs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−32.1%
Price agrees with the score
$40.00 vs $58.93 close before publication (Feb 2) · not market-adjusted
NVO chart →+35.8%
Price agrees with the score
$1417.54 vs $1044.13 close before publication (Feb 2) · not market-adjusted
LLY chart →
